biotech · Recurrent Head and Neck Cancer · Metastatic Head and Neck Cancer · PDSB
PDS Biotechnology
PDS Biotechnology Corp
PDS Biotechnology clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Princeton, USA
- Founded
- 2005
- Employees
- 32
- Programs
- 3
- Drugs
- 5
- Patents
- 11
PDS Biotechnology projects
3 ClinicalTrials.gov programs sponsored by PDS Biotechnology.
PDS Biotechnology has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Combination Treatment of PDS0101 and Pembrolizumab
PDS Biotechnology Corp
Recurrent Head and Neck Cancer
1 trial -
Pembrolizumab (KEYTRUDA®) and PDS0101
PDS Biotechnology Corp
Metastatic Head and Neck Cancer
1 trial -
U10-02-11-001
PDS Biotechnology Corp
High-risk HPV Infection and Biopsy-proven CIN1
1 trial
Frequently asked questions
How many clinical projects does PDS Biotechnology have?
3 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.